Research & Development



  隋越用力的揉搓了一下臉龐,就沿著建章宮高高的台階一步步的走下了建章宮。   這也是為什麼李陵膽敢深入敵陣的原因。2014春节彩票安排   鐘離遠搖搖頭道︰“我還是常侍,不是大長秋,陛下似乎沒有任命新的大長秋的意思。”2014互联网彩票趋势   有人擋住了陽光,隋越惱怒的睜開眼楮,卻看到了鐘離遠。   匈奴人的數量在迅速的變多,他們的營地布置也發生了變化,由一個營地變成了兩個,一東,一西,關閉了陽關通往西域的道路。23选5福利彩票   隋越淡淡的道︰“咱家不過是陛下的耳目,司馬大將軍如果要說公事,還是直接上奏陛下,將不能西征的前因後果說清楚為妙。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo